Exactly why I have amassed a PharmaCyte stock position over the last three and a half years. Like I've mentioned, I haven't been able to find another diabetes treatment which even remotely compares to PharmaCyte's Cell-in-a-Box®/Melligen cell combo. Far as I can tell, it has no competition because it is effectively a cure - no more needles, no more daily injections and no more insulin pumps for T1D diabetics because it cures both T1D and insulin-dependent T2D.
Consider the worldwide revenue potential of a cure for diabetes, one which requires no devices or pumps, just one initial injection of insulin-producing cells which can stay inside the human body for up to two years, possibly longer.
I'm super-excited for the upcoming trial in LAPC to begin but I will definitely be holding onto the majority of my position into diabetes trials and/or buyout.
News 
Market Data 
Discover 
